BioArctic (OM:BIOA B) - Stock Price, News & Analysis

BIOA B Stock Overview

Develops biological drugs for patients with disorders of the central nervous system in Sweden. More details

BIOA B fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	6/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 4.5% below our estimate of its fair value

Earnings are forecast to grow 62.23% per year

Analysts in good agreement that stock price will rise by 80.1%

Risk Analysis

Volatile share price over the past 3 months compared to the Swedish market

BioArctic AB (publ) Competitors

Bonesupport Holding

OM:BONEX

SEK 22.3b

Vitrolife

OM:VITR

SEK 28.4b

BioGaia

OM:BIOG B

SEK 10.5b

Devyser Diagnostics

OM:DVYSR

SEK 2.2b

Price History & Performance

Summary of all time highs, changes and price drops for BioArctic
Historical stock prices
Current Share Price	SEK 178.10
52 Week High	SEK 288.40
52 Week Low	SEK 137.70
Beta	-0.25
11 Month Change	11.52%
3 Month Change	11.94%
1 Year Change	-24.53%
33 Year Change	50.42%
5 Year Change	92.02%
Change since IPO	514.14%

Recent updates

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sep 01

Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Aug 15

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

Apr 13

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 19

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 03

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Dec 23

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Nov 12

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Jul 21

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Jul 15

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Jul 07

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

May 06

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Mar 13

Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher

Nov 30

We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn

Sep 16

We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow

Apr 04

Shareholder Returns

	BIOA B	SE Biotechs	SE Market
7D	17.6%	-3.8%	-1.9%
1Y	-24.5%	17.8%	12.5%

Return vs Industry: BIOA B underperformed the Swedish Biotechs industry which returned 17.8% over the past year.

Return vs Market: BIOA B underperformed the Swedish Market which returned 12.5% over the past year.

Price Volatility

Is BIOA B's price volatile compared to industry and market?
BIOA B volatility
BIOA B Average Weekly Movement	10.8%
Biotechs Industry Average Movement	9.1%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: BIOA B's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: BIOA B's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

Founded	Employees	CEO	Website
2000	96	Gunilla Osswald	www.bioarctic.se

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain.

BioArctic AB (publ) Fundamentals Summary

How do BioArctic's earnings and revenue compare to its market cap?
BIOA B fundamental statistics
Market cap	SEK 15.74b
Earnings (TTM)	-SEK 232.86m
Revenue (TTM)	SEK 166.84m

94.3x

P/S Ratio

-67.6x

P/E Ratio

Is BIOA B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIOA B income statement (TTM)
Revenue	SEK 166.84m
Cost of Revenue	SEK 75.29m
Gross Profit	SEK 91.55m
Other Expenses	SEK 324.41m
Earnings	-SEK 232.86m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 13, 2025

Earnings per share (EPS)	-2.63
Gross Margin	54.87%
Net Profit Margin	-139.57%
Debt/Equity Ratio	0%

How did BIOA B perform over the long term?

See historical performance and comparison

BIOA B Stock Overview

Rewards

Risk Analysis

BioArctic AB (publ) Competitors

OM:BONEX

SEK 22.3b

OM:VITR

SEK 28.4b

OM:BIOG B

SEK 10.5b

OM:DVYSR

SEK 2.2b

Price History & Performance

Recent News & Updates

Price target increased by 9.8% to kr321

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Eisai Co., Ltd. and BioAge Labs, Inc. Announce CHMP Issues Positive Recommendation for Approval of Lecanemab in the EU

BioArctic AB (publ) to Report Q2, 2025 Results on Aug 28, 2025

BioArctic AB (publ) Presents Nomination Committee

BioArctic AB (publ), Annual General Meeting, May 22, 2025

Recent updates

Price target increased by 9.8% to kr321

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Eisai Co., Ltd. and BioAge Labs, Inc. Announce CHMP Issues Positive Recommendation for Approval of Lecanemab in the EU

BioArctic AB (publ) to Report Q2, 2025 Results on Aug 28, 2025

BioArctic AB (publ) Presents Nomination Committee

BioArctic AB (publ), Annual General Meeting, May 22, 2025

Vice President of Human Resources exercised options and sold kr454k worth of stock

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 9.3% to kr291

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BioArctic AB (publ) Announces Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology

Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Price target decreased by 8.6% to kr336

New major risk - Share price stability

Insufficient new directors

Insider recently sold kr710k worth of stock

BioArctic AB (publ) Approves Leqembi [®] for the Treatment of Alzheimer's Disease in South Korea

First quarter 2024 earnings: Revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Consensus EPS estimates increase by 112%

Vice President of Human Resources exercised options to buy kr1.2m worth of stock.

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 15%

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Consensus revenue estimates fall by 16%

Consensus revenue estimates fall by 14%

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Independent Chairman recently bought kr1.1m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

VP & Head of Research recently sold kr2.8m worth of stock

VP & Head of Research exercised options to buy kr1.2m worth of stock.

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Consensus revenue estimates increase by 13%

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Consensus revenue estimates increase by 12%

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

Now 21% undervalued

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold kr6.5m worth of stock

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

Insider recently bought kr241k worth of stock

First quarter 2023 earnings released

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Independent Director recently sold kr3.3m worth of stock

Price target increased by 12% to kr400

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)